Prediabetes is dynamic and heterogeneous. Combining glycaemic subtypes with insulin secretion and sensitivity identifies those most likely to progress to #diabetes or regress to normoglycaemia #prediabetes #diabetesresearch #T2D link.springer.com/article/10.1... 🔓
October 29, 2026 at 12:03 PM
Prediabetes is dynamic and heterogeneous. Combining glycaemic subtypes with insulin secretion and sensitivity identifies those most likely to progress to #diabetes or regress to normoglycaemia #prediabetes #diabetesresearch #T2D link.springer.com/article/10.1... 🔓
How has newly diagnosed #Type2Diabetes evolved? A 180k+ cohort over 15 years: older, multimorbid, #MASLD surge, yet better glycaemic management. Uptake of #SGLT2i and #GLP1RA + >5-fold drop in sulfonylureas—a cardiorenal/weight paradigm shift link.springer.com/article/10.1... 🔓
October 27, 2026 at 12:03 PM
How has newly diagnosed #Type2Diabetes evolved? A 180k+ cohort over 15 years: older, multimorbid, #MASLD surge, yet better glycaemic management. Uptake of #SGLT2i and #GLP1RA + >5-fold drop in sulfonylureas—a cardiorenal/weight paradigm shift link.springer.com/article/10.1... 🔓
New issue alert! 📢
- CME on #neuro-oncolology
- Articles on #CKD, glycaemic optimisation, #asthma, #HIV, #TB and more!
Advance your clinical practice with expert‑led updates ⏬
www.sciencedirect.co...
- CME on #neuro-oncolology
- Articles on #CKD, glycaemic optimisation, #asthma, #HIV, #TB and more!
Advance your clinical practice with expert‑led updates ⏬
www.sciencedirect.co...
October 29, 2026 at 8:00 AM
New issue alert! 📢
- CME on #neuro-oncolology
- Articles on #CKD, glycaemic optimisation, #asthma, #HIV, #TB and more!
Advance your clinical practice with expert‑led updates ⏬
www.sciencedirect.co...
- CME on #neuro-oncolology
- Articles on #CKD, glycaemic optimisation, #asthma, #HIV, #TB and more!
Advance your clinical practice with expert‑led updates ⏬
www.sciencedirect.co...
Disease modification outcomes in type 2 #diabetes: a modified Delphi thelancet.com/journals/lan...
#T2D
#MedSky #EndoSky
#T2D
#MedSky #EndoSky
Disease modification outcomes in type 2 diabetes: a modified Delphi
Type 2 diabetes is a heterogeneous, progressive chronic condition for which management
has traditionally focused on glycaemic control and cardiovascular risk factors, rather
than focusing on altering ...
thelancet.com
October 30, 2026 at 11:33 AM
Disease modification outcomes in type 2 #diabetes: a modified Delphi thelancet.com/journals/lan...
#T2D
#MedSky #EndoSky
#T2D
#MedSky #EndoSky
Are you just aiming for weightloss or are you monitoring your blood sugar? Because either way if you're feeling fatigued, you need to eat now. Consider the glycaemic index of the carbs- choose slow release foods like sweet potato over regular, pasta over processed white bread?
October 29, 2026 at 2:43 AM
Are you just aiming for weightloss or are you monitoring your blood sugar? Because either way if you're feeling fatigued, you need to eat now. Consider the glycaemic index of the carbs- choose slow release foods like sweet potato over regular, pasta over processed white bread?
Are you just aiming for weightloss or are you monitoring your blood sugar? Because either way if you're feeling fatigued, you need to eat now. Consider the glycaemic index of the carbs- choose slow release foods like sweet potato over regular, pasta over processed white bread?
October 29, 2026 at 2:43 AM
Are you just aiming for weightloss or are you monitoring your blood sugar? Because either way if you're feeling fatigued, you need to eat now. Consider the glycaemic index of the carbs- choose slow release foods like sweet potato over regular, pasta over processed white bread?
Chazal et al evaluate #glycaemic variations in patients (diabetes mellitus, T2DM or non-diabetic) having #cardiac surgery and highlight the need of #new therapeutic targets to decrease postoperative variations
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00431-9/abstract
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00431-9/abstract
October 21, 2026 at 10:00 PM
Chazal et al evaluate #glycaemic variations in patients (diabetes mellitus, T2DM or non-diabetic) having #cardiac surgery and highlight the need of #new therapeutic targets to decrease postoperative variations
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00431-9/abstract
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00431-9/abstract
I guess one that's too complicated to state clearly on a website? I don't care about "clean," I care about glycaemic index.
October 20, 2026 at 9:37 AM
I guess one that's too complicated to state clearly on a website? I don't care about "clean," I care about glycaemic index.
📢 Deadline Extended! - #Special #Issue in #Pharmaceutics
🖊️ Advances in #Delivery Systems for #Antidiabetic #Drugs and Beyond Glycaemic Control
⏰ 30 June 2027
🔬 Dr. Ahmed Gedawy & Prof. Dr. Crispin R. Dass
📄 5 papers published—read & submit 👇
www.mdpi.com/journal/phar...
🖊️ Advances in #Delivery Systems for #Antidiabetic #Drugs and Beyond Glycaemic Control
⏰ 30 June 2027
🔬 Dr. Ahmed Gedawy & Prof. Dr. Crispin R. Dass
📄 5 papers published—read & submit 👇
www.mdpi.com/journal/phar...
October 21, 2026 at 9:41 AM
📢 Deadline Extended! - #Special #Issue in #Pharmaceutics
🖊️ Advances in #Delivery Systems for #Antidiabetic #Drugs and Beyond Glycaemic Control
⏰ 30 June 2027
🔬 Dr. Ahmed Gedawy & Prof. Dr. Crispin R. Dass
📄 5 papers published—read & submit 👇
www.mdpi.com/journal/phar...
🖊️ Advances in #Delivery Systems for #Antidiabetic #Drugs and Beyond Glycaemic Control
⏰ 30 June 2027
🔬 Dr. Ahmed Gedawy & Prof. Dr. Crispin R. Dass
📄 5 papers published—read & submit 👇
www.mdpi.com/journal/phar...
Boehringer's survodutide cleared Phase III in obesity and Type 2 diabetes, posting 13.1% weight loss versus 3.1% placebo over 76 weeks with meaningful glucose control gains. NEJM data.
Boehringer's survodutide hits Phase III endpoints in obesity plus T2D
SYNCHRONIZE-2 showed 13.1% average weight loss versus 3.1% on placebo after 76 weeks, with significant glycaemic improvements published in the NEJM.
biotech.disruptsmedia.com
October 13, 2026 at 12:30 PM
Boehringer's survodutide cleared Phase III in obesity and Type 2 diabetes, posting 13.1% weight loss versus 3.1% placebo over 76 weeks with meaningful glucose control gains. NEJM data.
TRIUMPH-2 findings suggest that retatrutide might advance the treatment of people with obesity and type 2 diabetes, showing bodyweight reduction alongside improvements in glycaemic control and cardiometabolic risk factors. Read more: spkl.io/633207VNIE #EASD2026
October 12, 2026 at 12:05 PM
TRIUMPH-2 findings suggest that retatrutide might advance the treatment of people with obesity and type 2 diabetes, showing bodyweight reduction alongside improvements in glycaemic control and cardiometabolic risk factors. Read more: spkl.io/633207VNIE #EASD2026
That's been updated since 2022. Metformin is multifactorial, acting on more than one tissue, & depending on dose. It interacts with both complex l and/or IV depending on dosage and tissue (gastro vs hepatic). And then there is muscle tissue.....
www.nature.com/articles/s42...
www.nature.com/articles/s42...
Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control - Nature Metabolism
Metformin is shown to exert its glucose-lowering and additional clinical effects through inhibition of mitochondrial complex I in the intestinal epithelium in mice.
www.nature.com
October 11, 2026 at 12:50 PM
That's been updated since 2022. Metformin is multifactorial, acting on more than one tissue, & depending on dose. It interacts with both complex l and/or IV depending on dosage and tissue (gastro vs hepatic). And then there is muscle tissue.....
www.nature.com/articles/s42...
www.nature.com/articles/s42...
I've been watching $LLY and Eli Lilly: Phase 3b Taltz+Zepbound shows biomarker synergy-psoriasis + glycaemic signal. https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/New-data-for-Eli-Lilly-and-the-Taltz-Zepbound-combination-54459692/
October 10, 2026 at 7:01 PM
I've been watching $LLY and Eli Lilly: Phase 3b Taltz+Zepbound shows biomarker synergy-psoriasis + glycaemic signal. https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/New-data-for-Eli-Lilly-and-the-Taltz-Zepbound-combination-54459692/
Increasing evidence indicates that #progression & #complications [of type 2 #diabetes] might be modifiable, but the absence of a core outcome set for disease modification limits trial design & intervention comparison www.thelancet.com/journals/lan...
#disease-modifying therapies
#MedSky #EndoSky
#disease-modifying therapies
#MedSky #EndoSky
Disease modification outcomes in type 2 diabetes: a modified Delphi
Type 2 diabetes is a heterogeneous, progressive chronic condition for which management
has traditionally focused on glycaemic control and cardiovascular risk factors, rather
than focusing on altering ...
www.thelancet.com
October 10, 2026 at 11:43 AM
Increasing evidence indicates that #progression & #complications [of type 2 #diabetes] might be modifiable, but the absence of a core outcome set for disease modification limits trial design & intervention comparison www.thelancet.com/journals/lan...
#disease-modifying therapies
#MedSky #EndoSky
#disease-modifying therapies
#MedSky #EndoSky
“Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.”
Publié ce jour dans @thelancet.com.
#MedSky #EndoSky
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
#MedSky #EndoSky
www.thelancet.com/journals/lan...
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Treatment with retatrutide resulted in substantial improvements in bodyweight and
was associated with improvements in glycaemic control in participants with obesity
and type 2 diabetes, with a safety ...
www.thelancet.com
October 10, 2026 at 11:11 AM
“Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.”
Publié ce jour dans @thelancet.com.
#MedSky #EndoSky
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
#MedSky #EndoSky
www.thelancet.com/journals/lan...
Century Therapeutics' iPSC-derived islet candidate CNTY-813 clears nonclinical hurdles. Consistent manufacturing, durable glycaemic control in model. IND filing tracked for Q4 2026.
Century Therapeutics' CNTY-813 hits IND-readiness milestones at EASD
Nonclinical data for the iPSC-derived islet therapy showed consistent manufacturing and durable glycaemic control, with an IND filing due in Q4 2026.
biotech.disruptsmedia.com
October 9, 2026 at 5:36 AM
Century Therapeutics' iPSC-derived islet candidate CNTY-813 clears nonclinical hurdles. Consistent manufacturing, durable glycaemic control in model. IND filing tracked for Q4 2026.
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial - The Lancet www.thelancet.com/journals/lan...
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Treatment with retatrutide resulted in substantial improvements in bodyweight and
was associated with improvements in glycaemic control in participants with obesity
and type 2 diabetes, with a safety ...
www.thelancet.com
October 8, 2026 at 12:34 AM
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial - The Lancet www.thelancet.com/journals/lan...
Although physical activity at any time of day improves health, some evidence suggests potential benefits of afternoon/evening activity for glycaemic and lipid-related outcomes in individuals at risk of type 2 diabetes #ExerciseTiming #MetabolicHealth link.springer.com/article/10.1... 🔓
The impact of physical activity and exercise timing on metabolic health among individuals at high risk of type 2 diabetes - Diabetologia
The timing of physical activity and exercise has been suggested to play a role in metabolic health. This narrative review synthesises current evidence on the impact of habitual physical activity and e...
link.springer.com
October 6, 2026 at 4:13 PM
Although physical activity at any time of day improves health, some evidence suggests potential benefits of afternoon/evening activity for glycaemic and lipid-related outcomes in individuals at risk of type 2 diabetes #ExerciseTiming #MetabolicHealth link.springer.com/article/10.1... 🔓
October 2, 2026 at 10:10 AM
えー
速攻で返信してすみませんが、炭水化物は危険ですな。
あととにかく白い食べ物が危険です。
白い小麦や白いお米白いパスタ白いお砂糖、などなど。
GI値(glycaemic index)というのを調べてみるとおもしろいです。
一緒に糖尿病にならないように頑張りましょう〜
東洋人って西洋人に比べてなりやすいみたいです。
速攻で返信してすみませんが、炭水化物は危険ですな。
あととにかく白い食べ物が危険です。
白い小麦や白いお米白いパスタ白いお砂糖、などなど。
GI値(glycaemic index)というのを調べてみるとおもしろいです。
一緒に糖尿病にならないように頑張りましょう〜
東洋人って西洋人に比べてなりやすいみたいです。
October 2, 2026 at 8:41 PM
えー
速攻で返信してすみませんが、炭水化物は危険ですな。
あととにかく白い食べ物が危険です。
白い小麦や白いお米白いパスタ白いお砂糖、などなど。
GI値(glycaemic index)というのを調べてみるとおもしろいです。
一緒に糖尿病にならないように頑張りましょう〜
東洋人って西洋人に比べてなりやすいみたいです。
速攻で返信してすみませんが、炭水化物は危険ですな。
あととにかく白い食べ物が危険です。
白い小麦や白いお米白いパスタ白いお砂糖、などなど。
GI値(glycaemic index)というのを調べてみるとおもしろいです。
一緒に糖尿病にならないように頑張りましょう〜
東洋人って西洋人に比べてなりやすいみたいです。
This framework aims to support outcome selection, consistency across trials, comparison of interventions, and evaluation of disease-modifying strategies in type 2 #diabetes thelancet.com/journals/lan...
#T2D #disease #modification #outcomes
#MedSky #EndoSky
#T2D #disease #modification #outcomes
#MedSky #EndoSky
Disease modification outcomes in type 2 diabetes: a modified Delphi
Type 2 diabetes is a heterogeneous, progressive chronic condition for which management
has traditionally focused on glycaemic control and cardiovascular risk factors, rather
than focusing on altering ...
thelancet.com
October 3, 2026 at 11:52 AM
This framework aims to support outcome selection, consistency across trials, comparison of interventions, and evaluation of disease-modifying strategies in type 2 #diabetes thelancet.com/journals/lan...
#T2D #disease #modification #outcomes
#MedSky #EndoSky
#T2D #disease #modification #outcomes
#MedSky #EndoSky
Type 2 #diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering long-term disease trajectory www.thelancet.com/journals/lan...
#disease #modification
#EASD2026
#disease #modification
#EASD2026
Disease modification outcomes in type 2 diabetes: a modified Delphi
Type 2 diabetes is a heterogeneous, progressive chronic condition for which management
has traditionally focused on glycaemic control and cardiovascular risk factors, rather
than focusing on altering ...
www.thelancet.com
October 2, 2026 at 8:00 AM
Type 2 #diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering long-term disease trajectory www.thelancet.com/journals/lan...
#disease #modification
#EASD2026
#disease #modification
#EASD2026
New international expert recommendations on inpatient use of CGM, insulin pumps and AID in non-critically ill hospitalised adults—covering selection criteria, clinical workflows, glycaemic metrics and targets, and more link.springer.com/article/10.1... 🔓️
An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults - Diabetologia
There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps and automated insulin delivery (AID) systems in hospital…
link.springer.com
October 1, 2026 at 3:03 PM
New international expert recommendations on inpatient use of CGM, insulin pumps and AID in non-critically ill hospitalised adults—covering selection criteria, clinical workflows, glycaemic metrics and targets, and more link.springer.com/article/10.1... 🔓️
Published in @thelancet.com
#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026
#MedSky #EndoSky
#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026
#MedSky #EndoSky
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Treatment with retatrutide resulted in substantial improvements in bodyweight and
was associated with improvements in glycaemic control in participants with obesity
and type 2 diabetes, with a safety ...
www.thelancet.com
October 1, 2026 at 7:44 AM
Published in @thelancet.com
#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026
#MedSky #EndoSky
#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026
#MedSky #EndoSky